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Abstract: Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of 
C1 esterase inhibitor (C1-INH). HAE has traditionally been divided into two subtypes. Unique 
among the inherited deficiencies of the complement system, HAE Types I and II are inherited 
as an autosomal dominant disorder. The generation of an HAE attack is caused by the depletion 
and/or consumption of C1-inhibitor manifested as subcutaneous or submucosal edema of the 
upper airway, face, extremities, or gastrointestinal tract. Attacks can be severe and potentially 
life-threatening, particularly with laryngeal involvement. Despite the availability of C1-INH 
for the treatment of HAE since the 1980s in Europe and other countries, HAE treatment in 
the United States was limited to androgen therapy. The human plasma-derived C1 esterase 
  inhibitor (CinryzeTM), distributed by Lev Pharmaceuticals, was approved in October 2008 for 
the   prevention of HAE attacks based on the results of a phase III clinical trial. This review aims 
to describe the history of C1-INH replacement in HAE as well as the pharmacology, efficacy 
and safety of C1-INH, concentrating on Cinryze as the first approved chronic replacement 
treatment for the prophylaxis of HAE attacks.
Keywords: hereditary angioedema, C1 esterase inhibitor, Cinryze, prophylaxis, angioedema
Introduction
Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of 
C1 esterase inhibitor (C1-INH). The disorder results from mutations of the C1-INH 
gene located on chromosome 11.1,2 Donaldson and Evans first recognized that C1-INH 
was deficient in the plasma of patients with HAE in 1963.3 Unique among the inherited 
deficiencies of the complement system, HAE Types I and II are inherited as an auto-
somal dominant disorder, with equal occurrence among men and women. Low levels 
of both C1-INH proteins distinguish Type I HAE, which accounts for approximately 
80% to 85% of all HAE cases. Type II HAE, which occurs in 15% to 20% of patients, 
results from decreased functional activity of the C1-INH gene, but with normal   C1-INH 
levels.4,5 Recently, a new subtype of HAE, Type III, has been described in the literature. 
Type III is characterized by an X-linked dominant inheritance and initially observed 
exclusively in women and is associated with normal levels and function of C1-INH.6 
Most cases appeared to be estrogen induced;7 however, more recently males have been 
identified that appear to have type III HAE, but with normal levels of C4, C1-INH-A 
and C1-INH-F.
Generation of HAE attacks are caused by the depletion and/or consumption of 
C1 inhibitor. The role of C1-INH in regulation of the contact system activation, via 
inactivation of plasma kallikrein and factor XIIa, was discovered during the 1970s Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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as the amount of C1-INH found in 1 mL of plasma. C1-INH 
was given to 3 of the 8 patients during asymptomatic periods. 
The remaining patients were given the inhibitor during acute 
attacks. Administration of C1-INH during acute attacks was 
shown to reduce the severity and duration of symptoms and 
signs of the acute attack. No adverse reactions were noted 
in relation to the administration of C1-INH concentrate. 
However, because of the HIV crisis in the mid 1980s research 
into C1 esterase replacement in the US ceased. In Europe 
research continued and C1-INH inhibitor was approved for 
treatment of acute attacks of HAE.
In 1989, Bork described a patient treated with   prophylactic 
C1-INH. The patient was treated with intravenous concen-
trate during a period of 1 year. The dose was determined 
empirically. The patient required C1-INH concentrate every 
fourth or fifth day and showed clinical improvement with 
almost complete cessation of attacks. In addition, there were 
no side effects noted during the treatment time course.21
The first randomized double blind control trial of C1-INH 
used for prophylaxis was completed with purified and vapor 
heated plasma in 1996.22 A prophylactic group of 6 patients 
was evaluated in a cross-over study in which subjects were 
randomly assigned to receive C1-INH infusion every 3 days 
in two different 17-day treatment periods. Disease activity 
was reduced 60% during the C1-INH treatment period.
In a previous study by Zuraw et al,23 22 patients were 
investigated over a 24-week period. Subjects received   
C1-INH 1000 U twice weekly or placebo for 12 weeks and 
then randomized to the other arm. Results demonstrated 
that subjects had fewer attacks during the C1-INH treat-
ment period than the placebo period (P  0.0001).23 While 
on chronic replacement, as compared to when subjects were 
on placebo, subjects not only had fewer attacks, but when 
they had attacks, the attacks were less severe and shorter in 
duration. Of the 22 patients, 2 worsened while on chronic 
replacement therapy and one had no change in attacks.
Pharmacology  
and pharmacokinetics
C1-INH is a naturally occurring single chain glycoprotein in 
human blood consisting of 478 amino acids and a molecular 
weight of 105 kDa. As a serine protease inhibitor, the main 
function of C1-INH is to regulate the activity of serine pro-
teinases. The biologic half-life of C1-INH in healthy subjects 
is 64 ± 1.4 hours suggesting that treatment every 3 days is 
necessary to restore C1-INH levels24 (Figure 1a).
and 1980s.8 C1-INH is the primary regulator of the classic 
complement pathway activation via inactivation of C1r and 
C1s.9 The low plasma concentration of functionally active 
C1-INH permits overactivation of the kallikrein-kinin 
system, the classical complement pathway, the fibrinolytic 
system and the coagulation system, with release of vasoac-
tive peptides among which bradykinin is considered to be 
most important.10–12 Bradykinin is released by cleavage of 
kininogen by kallikrein and it is capable of inducing edema 
as a result of its effects on vasodilation and microvessel 
permeability.13,14
The exact prevalence of HAE is not known, but it has 
been estimated to range from 1:10,000 to 1:150,000 in the 
general population. This suggests that there are 2000 to 
30,000 affected patients in the United States (US).14 Patients 
with HAE typically begin to swell in childhood and often 
experience increase symptoms beginning about the time of 
puberty.15
Clinically, HAE is characterized by episodic recurrent 
episodes of subcutaneous and sub-mucosal angioedema. 
Swelling affects the hands and feet but also involves the 
  genitalia, trunk, face, upper airways, larynx, and gastro-
intestinal tract.16 The disease is characterized by swell-
ing, which is not associated with urticaria, that does not 
respond to antihistamines, corticosteroids or epinephrine 
and usually subsides spontaneously in 72 hours.17 In one 
study, abdominal attacks were reported in more than 93% 
of patients and composed almost 50% of all angioedema 
attacks.18 However, skin swellings appear to be the most 
frequent symptoms of HAE.19
A positive family history of angioedema is present in 
most patients, although up to 25% of patients have negative 
family histories with a de novo C1 inhibitor mutations.18 
Thus, the absence of a family history in the presence of 
typical symptoms should not be a deterrent from making 
the diagnosis. Even within families with the same genetic 
aberration symptoms vary considerably and it is not unusual 
for one family member to have severe recurrent attacks and 
another to be relatively free of symptoms.
History of C1-INH use  
for prophylaxis in HAE
The first published manuscript on the treatment of HAE with 
C1-INH was published in 1980 by Gadek et al.20 During this 
study, the C1-INH protein was removed from pooled plasma 
via chromatography. They referred to 1 unit (U) of C1-INH Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Waytes et al22 demonstrated an increase in the level of 
C1 inhibitor after the initial infusions of concentrate, to a 
mean of 85% of normal values. Twenty-four hours after the 
infusion, the mean levels of C1 inhibitor were approximately 
70% of normal. At 72 hours values fell to 48% of normal 
value which is still significantly above the baseline level. 
Therefore, it was suggested that for prophylaxis, C-1-INH 
could be administered every 3 to 4 days given the level of 
C1-INH at the end of that timeframe. Unlike C-1-INH,   
C4 levels do not have a sharp rise and fall within a 72-hour 
period, suggesting that the biologic half life of C1-INH may 
exceed the serum half life. C4 levels increase more slowly 
and after administration of C1 inhibitor every 3 to 4 days 
levels of C4 persist within the normal range.22
Figure 1 A) Infusion of C1 esterase every third day in subjects with HAE and associated serum levels of C1 esterase inhibitor (C-1-I) compared with serum levels from 
normal subjects and those with HAE receiving placebo infusions. B) C4 serum levels in normal patients, and those with HAE receiving placebo or during infusion of C1 
esterase inhibitor (C-1-I).
Modified from Waytes et al.22
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The pharmacokinetics of the human plasma-derived 
C1-INH Cinryze™ were analyzed in a randomized, parallel 
group, open label pharmacokinetics study.25 The study was 
performed in patients with documented HAE who were cur-
rently asymptomatic. The patients received either a single 
dose of 1000 U or 1000 U followed by a   second 1000 U 
60 minutes later. All doses were administered intravenously. 
There have been no additional studies to date evaluating 
pharmacokinetics particularly in special patient popula-
tions. There is a dearth of data on the pharmacokinetics 
of C1-INH. It is not known to what extent gender, race, 
age, disease severity or the presence of renal or hepatic 
impairment affects C1-INH levels when being replaced. In 
asymptomatic patients, the results showed that the drug has 
a long half life and slow clearance. The mean half-lives of 
Cinryze were 56 hours (range 11 to 108 hours) for a single 
dose and 62 hours (range 16 to 152 hours) for the double 
dose, as shown in Table 1. Administration of Cinryze led to 
an increase in the concentrations of C1-INH and complement 
C4 over baseline values. Both of these concentrations were 
higher following double dose than a single dose. However, 
administration of a second dose 60 minutes after the first did 
not follow linear kinetics.25
As noted above, the safety and efficacy of Cinryze used 
as prophylaxis therapy showed a reduction in the incidence, 
severity, and duration of HAE attacks without any associated 
significant adverse events. These data from the single ran-
domized, double blind, placebo controlled multi-center cross-
over study have not yet been published.25 The study consisted 
of 24 patients who were screened to confirm a diagnosis of 
HAE and a history of at least two HAE attacks per month. 
The patients with a mean age of 38.1 years (age range 9 to 
73 years) were randomized to one of two treatment groups. 
The first group received Cinryze prophylaxis for 12 weeks 
followed by 12 weeks of placebo prophylaxis. The other 
group was randomized to placebo prophylaxis for 12 weeks 
followed by 12 weeks of Cinryze prophylaxis. Patients 
were given blinded injections every 3 to 4 days. Patients 
  subsequently recorded all angioedema symptoms daily. An 
attack was defined as the subject-reported indication of swell-
ing at any location following a report of no swelling on the 
previous day. Efficacy was based on the number of attacks 
during the 12 week period while receiving Cinryze compared 
to the number of attacks during the placebo treatment period. 
Patients treated with Cinryze had a 66% reduction in days of 
swelling (P  0.0001), and decreases in the average severity 
of attacks (P = 0.0006) and the average duration of attacks 
(P = 0.0023) as shown in Table 2.25 No studies to date have 
compared Cinryze to other agents used to treat HAE.
Dosing strategy
Cinryze is available in single-use vials that contain 500 U per 
vial and is supplied as a single glass vial of powder to be 
  reconstituted with 5 mL sterile water for injection. Two 500 U 
vials are needed to make a complete dose. The reconstituted 
solution must be used within 3 hours of reconstitution. The 
solution is drawn through the sterile filter needle into a   sterile 
disposable syringe. The reconstituted solution should be 
  colorless to slightly blue and free from visible particle. The full 
dose of 1000 U (reconstituted in 10 mL) of Cinryze is admin-
istered by intravenous injection at a rate of 1 mL per minute 
over 10 minutes.25
Use in special populations
Cinryze is classified as Pregnancy Category C. No animal 
data are available on use during pregnancy. No adequate 
and well-controlled studies were conducted in pregnant 
women during the initial trials. Therefore, it is unknown 
whether Cinryze can cause fetal harm when administered 
to a pregnant woman or can affect reproduction capacity. 
Table 1 Mean pharmacokinetic parameters of functional C1 
inhibitor (Cinryze)
Parameters Single dose Double dose
Cbaseline (units/mL) 0.31 ± 0.20 (n = 12) 0.33 ± 0.20 (n = 12)
Cmax (units/mL) 0.68 ± 0.08 (n = 12) 0.85 ± 0.12 (n = 13)
Tmax (h) 3.9 ± 7.3 (n = 12) 2.7 ± 1.9 (n = 13)
AUC(0-t) (units*h/mL) 74.5 ± 30.3 (n = 12) 95.9 ± 19.6 (n = 13)
CL (mL/min) 0.85 ± 1.07 (n = 7) 1.17 ± 0.78 (n = 9)
Half-life (h) 56 ± 36 (n = 7) 62 ± 38 (n = 9)
Data from Cinryze package insert.25
Abbreviations: AUC, area-under-the-curve concentration; Cmax, peak concentration; 
Tmax, time to peak concentration.
Table 2 Clinical trial secondary efficacy outcomes
   Cinryze 
 N = 22
Placebo  
N = 22
Treatment 
effect P value
Mean severity of 
HAE attacks  
(score from  
1 to 3) (SD)
1.3 (0.85) 1.9 (0.36) 0.0006
Mean duration 
of HAE attacks  
(days) (SD)
2.1 (1.13) 3.4 (1.4) 0.0023
Days of  
swelling (SD)
10.1 (10.73)  29.6 (16.9)  0.0001 
Data from Cinryze package insert.25
Abbreviation: HAE, hereditary angioedema.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Baker et al26 presented data on six pregnant women all of 
whom had normal healthy deliveries while on Cinryze being 
used as prophylaxis. Subjects received 1000 U of Cinryze 
replacement 1 to 2 times per week with benefit. Since then, 
another patient was reported who was in her second trimester 
and had no difficulties in regards to her pregnancy while on 
C1-INH replacement. The number of attacks and number 
of emergency medical visits were reduced by 85%. No 
adverse events secondary to Cinryze were reported and the 
therapy reportedly was tolerated well.26
At the present time, no data are available to suggest 
that C1-INH replacement is beneficial or harmful for the 
  newborn or mother during lactation. It is suggested that 
  caution should be exercised when administering Cinryze to 
a nursing woman, but this is due to the lack of available data. 
It is unknown whether Cinryze is excreted in human milk. 
The lack of data suggests that therapy should only be used 
during lactation when benefit outweighs risk and only after 
informed consent has been given by the patient.
The safety and effectiveness of Cinryze have not been 
established in neonates, infants, or children. Previous data 
found that very high doses of C1-INH given to premature 
neonates without HAE can predispose to hypercoagulation 
and thrombotic events.27 The only information suggesting the 
safety of C1-INH replacement is from three of the 24 subjects 
that completed the prophylaxis efficacy study who were under 
the age of 18 years. The youngest in the study was 9 years 
of age. Benefit and adverse events seemed to be similar to 
those over the age of 18 years of age. In addition, the study 
did not include sufficient numbers of subject 65 years of age 
and older to determine whether they respond differently from 
younger subjects.
Safety and tolerability
As noted, Cinryze was well tolerated during the clinical trial. 
Most of the observed drug related adverse effects were mild. 
The most common drug related adverse reactions observed at 
a rate 5% were upper respiratory tract infections, sinusitis, 
rash, and headache.25 There were severe adverse reactions 
that were thought to be unrelated to the study drug. These 
included death due to non-catheter related foreign body 
embolus, pre-eclampsia resulting in emergency cesareansec-
tion, stroke, and exacerbation of HAE attacks.
Thrombotic events were reported in association with 
other C1-INH products when used off-label at high doses. 
The thrombotic adverse events occurred during clinical trials 
for another indication and at doses of 4000 Us given over 
approximately 5 hours (an average dose of 57 U/kg) and 
9000 Units given over a 7-day period.27 At least one case of 
a thrombotic event has been reported to the Food and Drug 
Administration (FDA) during the Cinryze postmarketing 
period; however, it is not clear whether the thrombosis was 
secondary to an indwelling catheter, C1-INH or the com-
bination of both.
In vitro and in vivo animal thrombogenicity studies 
with Cinryze showed a potential for clot formation when 
administered at doses 14 times the recommended clinical 
dose (greater than 200 U/kg). This is also supported by ani-
mal studies when given intravenous administration of other 
C1-INH products.28
Because Cinryze is derived from human plasma, there 
is an inherent risk of viral transmission with its use. Steps 
designed to reduce the risk of viral transmission include 
screening donors at U.S. licensed blood collection centers. 
Donors are screened for infection with human immunode-
ficiency virus (HIV-1/HIV-2), hepatitis B virus, hepatitis C 
virus, and parvovirus B19. In addition, to reduce the pos-
sibility of viral transmission the units of plasma are not 
released until the donor returns in 3 months and if at that 
time the serologies are negative the plasma is released for 
processing. This time interval helps assure that HIV is not 
missed since during the window phase of infection HIV may 
be present even though serologies are negative. The use of 
two independent viral reduction steps in the manufacturing 
of Cinryze further reduces the possibility of viral transmis-
sion and includes pasteurization (heat treatment at 60°C 
for 10 hours in solution with stabilizers) and nanofiltration 
through two sequential 15 nm Planova filters.25
Cinryze is contraindicated in patients with any known 
hypersensitivity reactions to any constituents. An interesting 
concern arises when trying to distinguish between an acute 
angioedema attack versus a hypersensitivity reaction and 
as with other products used to treat HAE the occurrence of 
hypersensitivity may be over estimated secondary to HAE 
attacks mimicking hypersensitivity reaction.
No drug interaction studies have been conducted.
FDA approval details
The human plasma-derived C1-INH, Cinryze, distributed 
by Lev Pharmaceuticals, was approved in October 2008 
for the prevention of HAE attacks based on the results of 
the phase III clinical trial. It is manufactured by Sanquin 
Blood Supply Foundation Amsterdam, The Netherlands. 
Sanquin is also a producer for C1-INH in Europe. The 
FDA has requested that postmarketing studies be performed 
to address the following issues to include the optimal dose Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Table 3 HAE prophylactic therapy consideration criteria (goal 
of therapy: enable each HAE patient to live as normal a life as 
possible
Consideration criteria Prophylactic therapy
Frequency of attacks 1/month
Rapid progression of attacks Yes
Timely access to care No
History of laryngeal attacks Yes
Emergency visit to physician/hospital 3/year
Intubation due to HAE Yes
Hospitalized due to HAE 1/year
ICU due to HAE Yes
Missed days of school or work 10–15 days/year
Impacts lifestyle (vacation, family, sports) Yes
Analgesic dependency Yes
Notes: These therapy consideration criteria are for guidance only. Therapy   decisions 
are always based on close consultation between physician and patient on what the 
best course of therapy should be for a patient’s particular needs, problems and 
concerns.
Adapted from Craig et al.30
Abbreviation: HAE, hereditary angioedema.
for prophylaxis in males and females, immunogenicity and 
long-term safety. Currently, there are no submitted data on 
the safety profile of an intensified dose schedule of Cinryze 
for routine prophylaxis.
Table 4 A Comparison of approved and developing treatments for HAE in the USA
   Method of  
production
Mechanism of  
action
Half-life  Method of  
treatment
FDA status 
FFP (fresh frozen  
plasma)
Blood product Replaces C1 esterase inhibi-
tor
Long IV Used, but not approved 
for treatment of acute 
HAE attacks.
Androgens Traditional therapeutics Induces C1 esterase  
inhibitor production
long Oral Approved for HAE 
prophylaxis
Antifibrinolytics Traditional therapeutics Decreases activation  
of factor 12
Long Oral Prophylaxis for HAE
Berinert® P Plasma concentrate C1 inhibitor 24–46.5 h IV FDA approved for 
treatment of acute 
attacks
Cinryze™ Plasma concentrate C1 inhibitor 24–46.5 h IV FDA approved for 
chronic replacement or 
prophylaxis of HAE
Rhucin® Recombinant protein C1 inhibitor 3 h IV Pending resubmission 
for FDA approval
Ecallantide Recombinant protein Kallikrein inhibitor 1–4 h SC Approved for 
  treatment of acute 
HAE attacks
Icatibant 
 
 
Synthetic peptide 
 
 
Bradykinin-2 receptor 
antagonist 
 
1–4 h 
 
 
SC 
 
 
Phase III studies being 
performed at the 
present time for FDA 
approval
Abbreviations: HAE, hereditary angioedema; IV, intravenous; SC, subcutaneous.
Data for using Cinryze to treat active HAE attacks has 
been submitted to FDA, but Viropharma did not receive an 
approval for Cinryze for acute attacks of HAE. Open label 
data were presented at the American College of Allergy, 
Asthma and Immunology (ACAAI) annual meeting in 2008 
for the treatment of acute attacks with Cinryze. Dr. Bruce 
Zuraw presented data titled: “Results of open-label admin-
istration of nanofiltered C1-inhibitor for the treatment of 
acute HAE attacks”.29 The study enrolled 88 subjects with 
documented HAE. Patients were screened and enrolled in 
an acute treatment open-label protocol. Eligible subjects 
received open-label injections of Cinryze for acute attacks 
of angioedema occurring at any anatomical site and could 
receive a second open-label injection of Cinryze 60 minutes 
later if they had not improved. Twenty-four subjects were 
followed for greater than one year. Throughout the study, 
447 acute attacks were treated in 82 subjects who had at 
least 1 attack. The primary locations of treated attacks 
were extremities, facial, gastrointestinal, genitourinary, and 
laryngeal. The median time to improvement was 30 minutes 
in the 447 attacks that occurred, and 93.4% of patients 
reported improvement in symptoms within 4 hours. This 
was noted regardless of how many times they had previously 
received Cinryze. None of the subjects in this study treated Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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for laryngeal attacks required hospitalization or intubation. 
Despite this positive data, the P value for the primary outcome 
did not reach significance and the drug was not approved in 
the US for use in acute attacks. There were no serious adverse 
reactions thought to be related to Cinryze administration.
Conclusions
The recommended dose for HAE prophylaxis is 1000 units 
(two 5 mL vials) every 3 or 4 days. Thus, a maximum 
of 10,000 U are considered medically necessary per 30 days 
for HAE prophylaxis. The current wholesale price for Cin-
ryze is $2,437.50 per vial. With a therapeutic dosing regimen, 
the monthly cost of therapy would range from $36,562 to 
$48,750 per patient. This cost is a major burden on the patient 
even if the patient needs to pay a small co-pay.
Controversy exists on when to treat people with chronic 
replacement therapy, especially since medications such as 
androgens are effective, inexpensive and often tolerated 
well at low doses30 as shown in Table 3. It appears that 
patients with severe disease, those who fail to be controlled 
with androgens, or those with adverse events to androgens 
are good candidates for Cinryze chronic replacement 
therapy.
Further studies need to be conducted for special popu-
lations including pediatric patients, geriatric patients, and 
women during pregnancy. Also, dose escalation studies in 
those that are not controlled on approved doses of Cinryze 
are needed and according to the Clinical Trials Website are 
being conducted at the present time. Safety when using 
higher doses is important because of the prior evidence 
of thrombotic events in neonates treated with high doses 
of C-1-INH.
Postmarketing surveillance will also be important 
  especially since Cinryze was approved for chronic replace-
ment therapy based upon safety from a limited number of 
subjects. It appears that phase III studies will need to be 
repeated before approval of Cinryze for acute attacks. The 
use of Cinryze on demand at the time of prodromal symptoms 
should be effective in preventing an acute attack, but this 
study still needs to be performed.31 In addition, short-term 
prophylaxis, such as treatment before dental work and sur-
gery, need to be performed to confirm the efficacy and safety 
when using Cinryze for short-term prophylaxis.
In summary, Cinryze provides replacement therapy in 
those that have deficiency of the protein and thus is a physi-
ologic approach to therapy and hopefully will add significantly 
to the quality of life in patients that have HAE. It is anticipated 
that the safety and tolerance will continue to be benign and 
acceptable. As other medications become   available   (Kalbitor® 
Berinert®) and still others are approved (Icatibant®) for use 
in the US it will be interesting to see how the use of Cinryze 
evolves over the next 5 to 10 years (Table 4).
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